Trevi Therapeutics (TRVI) Tops Q3 EPS by 2c
Tweet
Share
E-mailGet Alerts TRVI Hot Sheet
Join SI Premium – FREE
Trevi Therapeutics (NASDAQ: TRVI) reported Q3 EPS of ($0.08), $0.02 better than the analyst estimate of ($0.10).
For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades Graphic Packaging Holding Company (GPK) to Overweight
- Bernstein SocGen Group Starts Amphenol (APH) at Outperform
- JPMorgan Downgrades Shenzhen Inovance Tech (300124:CH) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
